Experimental weight loss drug retatrutide reduces knee pain in trials
Participants taking retatrutide lost one quarter of their body weight and experienced significant reductions in knee osteoarthritis pain, according to clinical trial results.
FTMQ Health, written by our newsroom0 views
Northwestern Now News reported that an experimental injectable weight loss drug called retatrutide helped participants lose up to 25 percent of their body weight. The drug also significantly reduced knee pain in people living with obesity and knee osteoarthritis. [1]
According to Northwestern Now News, the research was published in the New England Journal of Medicine and involved two phase 3 clinical trials. The trials included more than 1,000 human participants combined. Patients taking the highest dose of retatrutide lost approximately one quarter of their body weight on average. [1]
Northwestern Now News reported that a pooled analysis of the two studies showed about two thirds of participants taking the drug experienced at least a 50 percent reduction in knee pain. Everyday activities such as walking, climbing stairs, and standing up from a chair can be difficult for people with painful knee osteoarthritis who are overweight or have obesity. [1]
As FTMQ Health reported earlier, human clinical trials generate crucial safety and dosage data on human participants when testing experimental drugs. [4]
In short
- Retatrutide is an experimental injectable weight loss drug.
- Participants taking the highest dose lost about 25 percent of their body weight on average in two phase 3 trials.
- About two thirds of trial participants experienced at least a 50 percent reduction in knee pain.
- The two phase 3 clinical trials combined involved more than 1,000 human participants.
Sources
Every paragraph above points to the numbered items it rests on. Read the originals here.
- [1]Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trialsNorthwestern Now News, 9d ago (the report this story comes from)
Background
- [2]Bodybuilding supplement on Wikipedia
- [3]Servier muscular dystrophy drug fails trial FTMQ Health, 14d ago
- [4]Cancer trial drug may target tumors differently than originally believed FTMQ Health, 42d ago
Our newsroom writes these reports with the help of software, from the 4 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.
Related from FTMQ Health
Earlier reports of ours on the same people and subjects.
- Pennington Biomedical launches weight loss study for young adultsMedical Science, 30d ago
- Servier muscular dystrophy drug fails trialTop Stories, 14d ago
- Modest weight loss in middle age improves cardiovascular health, study findsTop Stories, 28d ago
- Cancer trial drug may target tumors differently than originally believedTop Stories, 42d ago
- Structured support may limit weight regain after stopping GLP-1 drugsTop Stories, 41d ago
More in Medical Science
- CAR T cell therapy analysis reveals high inflammation but low mortality5h ago
- Diets rich in dairy and fruit linked to child height growth1d ago
- Meningococcal B vaccine prompts immune responses against gonorrhea in trial2d ago
- RIPK1 Inhibitors Match Placebo Safety in Human Clinical Trials2d ago
- Frontiers in Psychiatry collection highlights music interventions for mental health3d ago
- Shanghai dismisses researchers after gene editing trial death3d ago
Get the day in one email
Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments
Loading
Join the conversation
Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.
Already on the list? Enter the same address and we will send a sign-in link.
By signing up you agree to our terms and privacy policy. Unsubscribe any time.